Liminatus Pharma Completes InnocsAI Acquisition, Issuing 1.5 Billion Potential New Shares via Preferred Stock
LIMN sits 68% above its 52-week low of $0.095 on elevated volume (26× avg).
Summary
Liminatus Pharma has completed its acquisition of InnocsAI, issuing 11.19 million common shares and 158,881 shares of Series A Preferred Stock. Each preferred share is convertible into 10,000 common shares, representing a potential future issuance of over 1.5 billion common shares upon stockholder approval. This follows the definitive agreement announced on May 20th and an 8-K filed earlier today confirming the completion. The use of convertible preferred stock allowed the company to close the deal ahead of full stockholder approval, likely to comply with Nasdaq issuance limits, but introduces extreme potential dilution for existing shareholders, especially given the company's current market cap and ongoing Nasdaq delisting issues. Stockholder approval for the conversion of the Series A Preferred Stock will be a critical event to watch.
At the time of this announcement, LIMN was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.10 to $10.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.